PTK2 and neoplasm: FAK pharmacological inhibition should, on one hand, target tumour cells leading to increased sensitivity to chemotherapy and immune‐checkpoint inhibitor (Jiang et al, 2016), and, on another hand, impact activated fibroblasts reducing ECM remodelling and PDAC metastasis as we demonstrate here.